SCHEMBL3875005

SCHEMBL3875005

COC(=O)c1cccc(CNS(=O)(=O)c2ccc(-c3ccc(C#N)cc3)cc2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.66
NAMPT P43490 2/20 0.56
ADAMTS4 O75173 1/20 0.51
MMP13 P45452 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.50
KCNA5 P22460 1/20 0.50
KAT6A Q92794 1/20 0.48
POLB P06746 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
OPRK1 P41145 1/20 0.46
PLAU P00749 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
LSS P48449 1/20 0.45
ACLY P53396 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873213 0.88 CYP19A1 (0.70) CYP19A1NAMPTADAMTS4MMP13KAT6A
SCHEMBL3874748 0.88 NAMPT (0.60) CYP19A1NAMPTADAMTS4MMP13KCNA5
SCHEMBL3877412 0.84 CYP19A1 (0.62) CYP19A1NAMPTKCNA5KAT6APOLB
SCHEMBL3872490 0.82 CYP19A1 (0.68) CYP19A1NAMPTKCNA5POLBLOXL2
SCHEMBL14049769 0.80 NAMPT (0.52) CYP19A1NAMPTKCNA5POLBLOXL2
SCHEMBL3874284 0.80 CYP19A1 (0.58) CYP19A1NAMPTMMP13KAT6APOLB
SCHEMBL3883802 0.79 CYP19A1 (0.57) CYP19A1KAT6ALMNAHPGD
SCHEMBL3874725 0.78 ALDH1A1 (0.59) CYP19A1KAT6APOLBCA2OPRK1
SCHEMBL1169813 0.78 CYP19A1 (0.60) CYP19A1NAMPTKCNA5POLBOPRK1
SCHEMBL3871576 0.77 POLB (0.78) CYP19A1NAMPTKCNA5KAT6APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 CYP19A1 23/4885NAMPT 2223/4885ADAMTS4 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.